Monitoring Hypertension with Azilsartan Treatment With/Without Added Drug in PatientsWith/Without Comorbidity: An Observational Study (original) (raw)
2019, https://www.ijrrjournal.com/IJRR\_Vol.6\_Issue.10\_Oct2019/Abstract\_IJRR0054.html
Aims and Objectives of Study: Hypertension statistics had reported that approximately 9 million lives/per annum are at risk due to increased blood pressure. Azilsartan Medoxomil is an angiotensin inhibitor, widely used as a single treatment regime or in combination with other drugs is an FDA approved therapeutic that has a significant impact in hypertension patients. The present study is a prospective observational study with (a) Primary objective: to evaluate efficiency of Azilsartan (40mg / 80mg) as single treatment regime or with added drug, (b) Secondary objective: to assess the control statistics of hypertension in patients with/ without comorbidity. Methodology: A total of 120 patients were screened and 100 subjects fulfilled the inclusion criteria with a hypertensive cut off value of 130/80 mmHg. Patients were subjected to Azilsartan monotherapy dosage (40mg/80mg) and combinatorial Azilsartan treatment with added drug. The following data was collected and analyzed for all study subjects enrolled in this observational study: Demographic details, Comorbidity associated with hypertension, Measurements of Systolic blood pressure (SBP), Diastolic blood pressure (DBP), Measurements of Systolic blood pressure (SBP3m) and Diastolic blood pressure (DBP3m) after 3 months of drug treatment. Results: The study population was predominantly of 51-60 years age group. Prevalence of hypertension at a gender level clearly showed that male population with 63% enrollment in study are at an increased risk in comparison to 37% patient enrollment noted in female population. Medical comorbidity ailments including Coronary Artery Disease, Diabetes Mellitus, Rheumatic Heart Disease. Azilsartan dosage (40mg/80mg) with either single treatment regime or combinatorial treatment regime with added drugs caused effective reduction in blood pressure during the study period. Conclusion: Combinatorial treatment regimens of Azilsartan (40mg/80mg) along with added drug, proved more effective in significantly lowering blood pressure levels.
Related papers
Azilsartan: Current Evidence and Perspectives in Management of Hypertension
Hypertension continues to be global pandemic with huge mortality, morbidity, and financial burden on the health system. Unfortunately, most patients with hypertension would eventually require two or more drugs in combination to achieve their target blood pressure (BP). To this end, emergence of more potent antihypertensive drugs is a welcome sign. Angiotensin receptor blockers (ARBs) are cornerstones of hypertension management in daily practice. Among all ARBs, azilsartan is proven to be more potent in most of the head-to-head trials till date. Azilsartan is the latest ARB approved for hypertension with greater potency and minimal side effects. is review highlights the role of azilsartan in management of hypertension in the current era.
Azilsartan’s role in management of hypertension
2013
Abstract: Hypertension is a common disease that leads to significant cardiovascular morbidity and mortality. Adequate blood pressure control is essential in preventing end organ complications. Read this review and sign up to receive Research Reports in Clinical Cardiology journal here: http://www.dovepress.com/articles.php?article\_id=13911
Med pulse, 2018
INTRODUCTION Essential hypertension is a common cardiovascular disorder with sustained increase in blood pressure ≥140/90 mmHg. The elevated arterial pressure causes pathological changes in the vasculature and hypertrophy of the left ventricle. Hypertension is the principle cause of stroke that is a major risk factor for coronary artery disease (CAD) and its attendant complications like myocardial infarction and sudden cardiac death. It is also a major contributor to cardiac failure, renal insufficiency and dissecting aneurysm of aorta. 1 Hypertension is an increasingly prevalent chronic condition that is associated with serious morbidity and mortality. It is an important risk factor for the development and progression of cardiovascular disease (CVD), which is predicted to become the leading cause of death and disability worldwide by 2020. 2 As per the Registrar General of India and Million Death Study investigators (2001-2003), CVD was the largest cause of deaths in males (20.3%) as well as females (16.9%) and led to about 2 million deaths annually. In India, 23.10% men and 22.60% women over the age of 25 years suffer from hypertension. 3 Treating systolic blood pressure (SBP) and diastolic blood pressure (DBP) to targets that are <140/90 mmHg is ABSTRACT Background: Objectives of the study was to study the effect of Azilsartan 40mg once daily versus Telmisartan 40mg once daily in patients with Grade I-II essential hypertension. Methods: A prospective study was conducted at MGM Medical college and Hospital which included 80 patients in each group with Grade I-II essential hypertension. The sex, age, presenting illness, and family history of the patients were recorded. Investigations such as blood sugar, urine analysis, kidney function test, lipid profile, and ECG were performed before starting the treatment. Any adverse effects during the treatment were noted. Blood pressure was recorded at baseline and during follow-up. One group received Azilsartan 40mg once daily and another group Telmisartan 40mg once daily. Patients were followed-up every week for 5 weeks. Results: Patients receiving Azilsartan 40mg and Telmisartan 40mg showed a significant fall (P <0.05) in systolic (SBP) at the end of fifth week, when compared to baseline and diastolic blood pressure (DBP) significant fall at fourth and fifth week. The difference in fall in SBP and DBP was insignificant between the groups, after first, second and third week (P >0.05). Adverse effects such as Nasopharyngitis, Upper respiratory tract inflammation, Gastroenteritis, headache, dizziness, and fatigue were reported with both drugs. Conclusions: Reduction of blood pressure with Azilsartan and Telmisartan was similar, but fall in blood pressure from baseline was highly significant in both groups.
A prospective comparative efficacy of azilsartan and telmisartan in hypertensive patients
International Journal of Basic & Clinical Pharmacology
Background: Hypertension (HT) is defined as either a sustained systolic blood pressure of greater than 140 mmHg or a sustained diastolic blood pressure of greater than 90 mmHg, according to joint national committee (JNC VIII) on hypertension.Methods: A prospective, open, randomized parallel group comparative study of AZL versus telmisartan was done in patients of stage-I HT. The study included 80 patients, 40 in each group (group I and group II) coming to the Department of Pharmacology, Mahatma Gandhi Medical College and Research Institute, Pillayarkuppam, Pondicherry from January 2016 to December 2017. The study was conducted over 8 weeks. Group-I, patients received azilsartan 40-80 mg per day in divided doses and group-II, patients received telmisartan 40-80 mg per day in divided doses according to severity of hypertension.Results: Patients receiving AZL 40 mg and telmisartan 40 mg showed a significant fall (p<0.05) in systolic blood pressure (SBP) and diastolic blood pressure ...
Loading Preview
Sorry, preview is currently unavailable. You can download the paper by clicking the button above.